Disufenton sodium

Chemistry

Disufenton sodium is the disulfonyl derivative of the neuroprotective nitrone spin trap phenylbutylnitrone or "PBN". PBN and its derivatives hydrolyze and oxidize in vitro to form respectively MNP-OH (AKA, NtBHA) and its parent spin-trap MNP.

Research

Disufenton sodium was under development at the drug company AstraZeneca. A 2005 phase-3 clinical trial called "SAINT-1" reported some efficacy in the acute treatment of ischemia injury due to stroke. However, a 2006 attempt to repeat this trial indicated no significant activity. After ruling out other causes, the authors tentatively attributed the positive results in the first trial to "chance". AstraZeneca then terminated the development programme.

Disufenton sodium has been researched as a potential treatment for use in brain tumors and cancers, including diffuse intrinsic pontine glioma (DIPG) and glioblastoma.

A compound (NHPN-1010) containing a combination of disufenton sodium and acetylcysteine has been researched as a potential treatment for tinnitus and hearing loss.

References

References

1. (September 1, 2021). "Use of Radical Oxygen Species Scavenger Nitrones to Treat Oxidative Stress-Mediated Hearing Loss: State of the Art and Challenges". Frontiers Media SA.
2. (August 2001). "NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat". Elsevier BV.
3. (December 2015). "Noise-Induced Neural Degeneration and Therapeutic Effect of Antioxidant Drugs". The Korean Audiological Society.
4. (February 2006). "NXY-059 for acute ischemic stroke". The New England Journal of Medicine.
5. (December 2006). "Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial". Stroke.
6. "Renovis: Press Release".
7. (November 2020). "OKlahoma Nitrone-007: novel treatment for diffuse intrinsic pontine glioma". Springer Science and Business Media LLC.
8. (March 3, 2021). "FDA grants fast track status to OKN-007 for diffuse intrinsic pontine glioma".
9. (May 20, 2020). "Phase Ib clinical trial of OKN-007 in recurrent malignant glioma.". American Society of Clinical Oncology (ASCO).
10. (January 2022). "A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone-based OKN-007". Wiley.
11. (January 7, 2021). "Electrophysiological assessment and pharmacological treatment of blast-induced tinnitus". *Public Library of Science (PLoS)*.
12. (November 2019). "Blast-induced tinnitus: Animal models". Acoustical Society of America (ASA).
13. "Congressionally Directed Medical Research Programs (CDMRP) Search Awards".
14. (July 27, 2020). "Hough Ear Institute receives $300K grant to support research treatments for hearing loss".